Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Molecular docking-guided synthesis of NSAID-glucosamine bioconjugates and their evaluation as COX-1/COX-2 inhibitors with potentially reduced gastric toxicity.

Authors: Jones Lipinski, Rachel A; Thillier, Yann; Morisseau, Christophe; Sebastiano Jr, Christopher S; Smith, Brian C; Hall, C Dennis; Katritzky, Alan R

Published In Chem Biol Drug Des, (2021 07)

Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are a powerful class of inhibitors targeting two isoforms of the family of cyclooxygenase enzymes (COX-1 and COX-2). While NSAIDs are widely used in the management of pain, in particular as a treatment for osteo- and rheumatoid arthritis, their long-term use has been associated with numerous on- and off-target effects. As the carboxylic acid moiety present in common NSAIDs is responsible for some of their adverse effects, but is not required for their anti-inflammatory activity, we sought to mask this group through direct coupling to glucosamine, which is thought to prevent cartilage degradation. We report herein the conjugation of commonly prescribed NSAIDs to glucosamine hydrochloride and the use of molecular docking to show that addition of the carbohydrate moiety to the parent NSAID can enhance binding in the active site of COX-2. In a preliminary, in vitro screening assay, the diclofenac-glucosamine bioconjugate exhibited 10-fold greater activity toward COX-2, making it an ideal candidate for future in vivo studies. Furthermore, in an intriguing result, we observed that the mefenamic acid-glucosamine bioconjugate displayed enhanced activity toward COX-1 rather than COX-2.

PubMed ID: 33955172 Exiting the NIEHS site

MeSH Terms: Anti-Inflammatory Agents, Non-Steroidal/adverse effects; Anti-Inflammatory Agents, Non-Steroidal/chemistry*; Catalytic Domain; Cyclooxygenase 1/metabolism*; Cyclooxygenase 2/metabolism*; Cyclooxygenase Inhibitors/adverse effects; Cyclooxygenase Inhibitors/chemistry*; Diclofenac/chemistry; Drug Design; Glucosamine/chemistry*; Glycoconjugates/adverse effects; Glycoconjugates/chemistry*; Mefenamic Acid/adverse effects; Mefenamic Acid/chemistry*; Molecular Docking Simulation; Protein Binding; Protein Conformation; Stomach; Structure-Activity Relationship

Back
to Top